Tumor neoantigens: building a framework for personalized cancer immunotherapy
Matthew M. Gubin(The University of Texas MD Anderson Cancer Center), Robert D. Schreiber(Parker Institute for Cancer Immunotherapy)
Cited by 631
Related Papers
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
|The Journal of Experimental Medicine|2011|1k
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas
|Breast Cancer Research|2012|198
Vav proteins control MyD88-dependent oxidative burst
|Blood|2006|83
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
|Blood Advances|2024|12
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
|Cancer Immunology Research|2024|6